Menu
Search
|

Menu

Close
X

OncoMed Pharmaceuticals Inc OMED.OQ (NASDAQ Stock Exchange Global Select Market)

2.16 USD
+0.00 (+0.00%)
As of Feb 23
chart
Previous Close 2.16
Open 2.19
Volume 23,830
3m Avg Volume 60,141
Today’s High 2.20
Today’s Low 2.06
52 Week High 10.86
52 Week Low 1.75
Shares Outstanding (mil) 37.86
Market Capitalization (mil) 81.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
18
FY16
25
FY15
26
EPS (USD)
FY17
-1.295
FY16
-3.182
FY15
-2.843
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
3.45
8.08
Price to Book (MRQ)
vs sector
--
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
--
15.60
LT Debt to Equity (MRQ)
vs sector
--
12.18
Return on Investment (TTM)
vs sector
-56.95
13.67
Return on Equity (TTM)
vs sector
--
15.40

EXECUTIVE LEADERSHIP

Perry Karsen
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Sunil Patel
Chief Financial Officer, Executive Vice President, Corporate Development and Finance and President, Since 2017
Salary: --
Bonus: --
John Lewicki
President, Executive Vice President - Research and Development, Since 2018
Salary: $364,727.00
Bonus: --
Austin Gurney
Senior Vice President, Molecular and Cellular Biology, Since
Salary: --
Bonus: --
Tim Hoey
Senior Vice President, Cancer Biology, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

800 Chesapeake Dr
REDWOOD CITY   CA   94063-4748

Phone: +1650.9958200

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

SPONSORED STORIES